Navigation Links
Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
Date:7/22/2009

ure. Talk to your doctor immediately if you experience unusually fast weight gain, fluid retention (swelling), shortness of breath, or unusual tiredness.

Do not take ACTOS if you have active liver disease. Your doctor should perform a blood test to check for liver problems before you start ACTOS and periodically thereafter. Talk to your doctor immediately if you experience nausea, vomiting, stomach pain, tiredness, loss of appetite, dark urine, or yellowing of the skin.

If you are of childbearing age, talk to your doctor before taking ACTOS, as it could increase your chance of becoming pregnant. Talk to your doctor if you are pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed. When taking ACTOS with insulin or sulfonylureas, you may be at risk for low blood sugar. Some people taking ACTOS may experience flulike symptoms, mild-to-moderate swelling of legs and ankles, anemia, and weight gain. Patients with diabetes should have regular eye exams. If you experience vision problems, consult your doctor immediately. Some patients have experienced visual changes while taking ACTOS.

Some people, particularly women, are at higher risk of having bone fractures while taking ACTOS. Other side effects may include cold-like symptoms, headache, sinus infection, muscle pain, tooth disorder, and sore throat.

Please visit the Takeda Pharmaceuticals North America, Inc. Web site at www.tpna.com for Complete Prescribing Information including the boxed warning about heart failure.

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical compa
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
8. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
9. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...ov. 20 Soligenix, Inc. (...y), formerly known as DOR BioPharma, Inc., a late-...it has formed a consortium to develop thermostable... acting vaccines. Soligenix received a $9.4 millio... Infectious Diseases (NIAID), a division of the Na...
(Date:11/19/2009)...ov. 19 In a series of ne..., Heska Corporation (Nasdaq: HSKA ) ("Heska" or t...w and improved website. The upgraded site is the ...rogramming to align the site with the company,s ne...go: http://www.newscom.com/cgi-bin/prnh/20000622...
(Date:11/19/2009)...Nov. 19 The D e al m...its Most Admired Corporate Dealmakers for the seco... its Most Admired Dealmaker in pharma/biotech for ...nd divestitures since January 2006. ,, Over the...tfolio with a focus on high-growth, innovation-dri...
Breaking Medicine Technology:Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6Heska Announces Launch of New Website 2Heska Announces Launch of New Website 3The Deal Names Abbott Top Dealmaker for Second Consecutive Year 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 3Response Times Vary for In Hospital Heart Attacks 53388 1Response Times Vary for In Hospital Heart Attacks 53388 2Blood Transfusions Not Linked to Long Term Problems 53386 1JAG Media Holdings Inc Announces Completion of Acquisition of CardioGenics Inc 53384 1JAG Media Holdings Inc Announces Completion of Acquisition of CardioGenics Inc 53384 2JAG Media Holdings Inc Announces Completion of Acquisition of CardioGenics Inc 53384 3JAG Media Holdings Inc Announces Completion of Acquisition of CardioGenics Inc 53384 4
... 10:00 a.m. today, Thursday, August 16, 2007, MAL... (Nasdaq: AUXL ) today announced that the Company...g Administration ("FDA") to,resume its phase III c...e,for injection), formerly referred to as AA4500, ...ompany will hold a conference call today,August 16...
...plemental New Drug Application in the Fourth ...ug. 16 Cephalon, Inc. (Nasdaq:,CEPH) today announ...cal,trial of FENTORA(R) (fentanyl buccal tablet) [...d with a broad range of chronic non-cancer pain,co...nce on the primary,endpoint. Results across the 12...
Other Medicine Technology:Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 2Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 3Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 4Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 5Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 6Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 2Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 3Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 4Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 5
(Date:11/20/2009)...ire-USNewswire/ -- The American Dental Association...ration (FDA) to establish appropriate classificati...oncern about the safety of whitening products that...fessional consultation or examination by a dentist...mically based tooth whitening or bleaching agents ...
(Date:11/20/2009)...wire-USNewswire/ -- The following is a statement b...Health Care Association: ,, "The Nevada Health ... Majority Leader Harry Reid for his leadership in ... protecting every Nevada seniors, ongoing access t...rength and viability of our state,s vital frontlin...
(Date:11/20/2009)...ildren with chronic kidney disease often fail to d...sits increasing a child,s risk for serious heart ... Children,s Center and other institutions. A repor... American Society of Nephrology. , Researchers...ing regular doctor visits to readings obtained via...
(Date:11/20/2009)...g 90-day supply, study finds , , FRIDAY,...supply of prescription drugs is up to one-third ch... a new study. , U.S. researchers analyzed 26,85...and 2005, and found that patients who bought a thr...d an average 29 percent in out-of-pocket costs. Af...
(Date:11/20/2009)...es increased food insecurity as many face problem ...swire/ -- Project Bread, the state,s leading anti-...oming annual status report on hunger in the Common...eport, caused by high unemployment, point to 554,0...er. Food insecurity has found its way into middle ...
Breaking Medicine News(10 mins):Health News:American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products 2Health News:High blood pressure easy to miss in children with kidney disease 2Health News:Three-Month Supply Lowers Drug Costs 2Health News:554,000 in Massachusetts Struggle to Put Food on the Table 2Health News:554,000 in Massachusetts Struggle to Put Food on the Table 3Health News:554,000 in Massachusetts Struggle to Put Food on the Table 4
..., Nov. 1 Arete Therapeutics Inc. today,announced ... lead compound,AR9281, for the treatment of hypert...e inhibitor of soluble epoxide hydrolase (s-EH), a...armacokinetics and pharmacodynamics for single asc...
... Nov. 1 Amedica Corporation, an,orthopedic implan...nologies, announced today that Ashok Khandkar, Ph....ice President Finance and Chief Financial,Officer,... Hotel in New York City. Mr. Khandkar and Mr. Gal...
...gland and PHILADELPHIA, November 1, Shire plc (LSE...ty biopharmaceutical company announces results for...ghts - Product sales up 41% to $543.1 million; -...ed to be at least 30% (Q2 guidance: at,least 25%)....
...nfirm environmental toxins play role in autism, as..., Nov. 1 The National Autism,Association (NAA) an...school districts to implement the "Greening Your S...nate the serious,dangers posed to children from da...
...wth Over Same Quarter Last Year - - 20%... - FY08 Revenue Projection Raised - ...ed - - Conference Call to be Held at 10:00 a.m....cal 2008 ended September 30, 2007, up 73% from $1....
...Calif., Nov. 1 The Maverick Saloon will,host a tr...ber 8, 2007 from,4 PM until 7 PM to raise research... that claimed the life of the much loved and respe...yvjoneshouse.com . The proceeds from the show wil...
Other Medicine News:Health News:Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent 2Health News:Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent 3Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 2Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 3Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 4Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 5Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 6Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 7Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 8Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 9Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 10Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 11Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 12Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 13Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 14Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 15Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 16Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 17Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 18Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 19Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 20Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 21Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 22Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 23Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 24Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 25Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 26Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 27Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 28Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 29Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 30Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 31Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 32Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 33Health News:National Autism Association and Deirdre Imus Environmental Center for Pediatric Oncology Announce National 'Greening Your School' Initiative 2
ApexPro CH
ISI Alumi-Hand
TeleRehab™ Advantage
ISI Ultra-Light Specialty Table
Medicine Products: